With 3.71 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.26 million shares. The 52-week range on SNDL shows that it touched its highest point at $2.36 and its lowest point at $1.25 during that stretch. It currently has a 1-year price target of $3.61. Beta for the stock currently stands at 3.35.
Price Performance and Earnings:
Three-month performance surged to 0.68% while six-month performance fell -26.24%. The stock lost -4.49% in the past year, while it has lost -9.15% so far this year. A look at the trailing 12-month EPS for SNDL yields -0.65 with Next year EPS estimates of -0.00.
Float and Shares Shorts:
At present, 260.49 million SNDL shares are outstanding with a float of 258.39 million shares on hand for trading. On Feb 29, 2024, short shares totaled 10.17 million, which was 3.89% higher than short shares on Jan 31, 2024. In addition to SNDL as the firm’s SNDL Inc., SNDX serves as its Syndax Pharmaceuticals, Inc.
Institutional Ownership:
Through their ownership of 9.21% of SNDL’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SNDL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
Dividends & Yield:
In terms of dividends, SNDL has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and SNDL currently yields $0.00. In the past year, SNDL’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, SNDL has a current buyback yield of $1.67. This was $1.67 for the TTM, and it was $– for the past five years.
